494 related articles for article (PubMed ID: 22443154)
1. Systematic review of efficacy and safety of buprenorphine versus fentanyl or morphine in patients with chronic moderate to severe pain.
Wolff RF; Aune D; Truyers C; Hernandez AV; Misso K; Riemsma R; Kleijnen J
Curr Med Res Opin; 2012 May; 28(5):833-45. PubMed ID: 22443154
[TBL] [Abstract][Full Text] [Related]
2. Adverse effects of transdermal opiates treating moderate-severe cancer pain in comparison to long-acting morphine: a meta-analysis and systematic review of the literature.
Tassinari D; Sartori S; Tamburini E; Scarpi E; Raffaeli W; Tombesi P; Maltoni M
J Palliat Med; 2008 Apr; 11(3):492-501. PubMed ID: 18363493
[TBL] [Abstract][Full Text] [Related]
3. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
4. A comparison of oral controlled-release morphine and oxycodone with transdermal formulations of buprenorphine and fentanyl in the treatment of severe pain in cancer patients.
Nosek K; Leppert W; Nosek H; Wordliczek J; Onichimowski D
Drug Des Devel Ther; 2017; 11():2409-2419. PubMed ID: 28860712
[TBL] [Abstract][Full Text] [Related]
5. Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study.
Sittl R; Likar R; Nautrup BP
Clin Ther; 2005 Feb; 27(2):225-37. PubMed ID: 15811486
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of transdermal buprenorphine and transdermal fentanyl in the treatment of neuropathic pain in AIDS patients.
Canneti A; Luzi M; Di Marco P; Cannata F; Pasqualitto F; Spinoglio A; Reale C
Minerva Anestesiol; 2013 Aug; 79(8):871-83. PubMed ID: 23558760
[TBL] [Abstract][Full Text] [Related]
7. Systematic review of tapentadol in chronic severe pain.
Riemsma R; Forbes C; Harker J; Worthy G; Misso K; Schäfer M; Kleijnen J; Stürzebecher S
Curr Med Res Opin; 2011 Oct; 27(10):1907-30. PubMed ID: 21905968
[TBL] [Abstract][Full Text] [Related]
8. A feasibility study of transdermal buprenorphine versus transdermal fentanyl in the long-term management of persistent non-cancer pain.
Mitra F; Chowdhury S; Shelley M; Williams G
Pain Med; 2013 Jan; 14(1):75-83. PubMed ID: 23320402
[TBL] [Abstract][Full Text] [Related]
9. Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain.
Allan L; Hays H; Jensen NH; de Waroux BL; Bolt M; Donald R; Kalso E
BMJ; 2001 May; 322(7295):1154-8. PubMed ID: 11348910
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and adverse effects of transdermal fentanyl and sustained-release oral morphine in treating moderate-severe cancer pain in Chinese population: a systematic review and meta-analysis.
Yang Q; Xie DR; Jiang ZM; Ma W; Zhang YD; Bi ZF; Chen DL
J Exp Clin Cancer Res; 2010 Jun; 29(1):67. PubMed ID: 20529380
[TBL] [Abstract][Full Text] [Related]
11. Gastrointestinal symptoms under opioid therapy: a prospective comparison of oral sustained-release hydromorphone, transdermal fentanyl, and transdermal buprenorphine.
Wirz S; Wittmann M; Schenk M; Schroeck A; Schaefer N; Mueller M; Standop J; Kloecker N; Nadstawek J
Eur J Pain; 2009 Aug; 13(7):737-43. PubMed ID: 18977159
[TBL] [Abstract][Full Text] [Related]
12. Transdermal fentanyl: an updated review of its pharmacological properties and therapeutic efficacy in chronic cancer pain control.
Muijsers RB; Wagstaff AJ
Drugs; 2001; 61(15):2289-307. PubMed ID: 11772140
[TBL] [Abstract][Full Text] [Related]
13. Opioids for cancer pain - an overview of Cochrane reviews.
Wiffen PJ; Wee B; Derry S; Bell RF; Moore RA
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD012592. PubMed ID: 28683172
[TBL] [Abstract][Full Text] [Related]
14. Buprenorphine for treating cancer pain.
Schmidt-Hansen M; Bromham N; Taubert M; Arnold S; Hilgart JS
Cochrane Database Syst Rev; 2015 Mar; 2015(3):CD009596. PubMed ID: 25826743
[TBL] [Abstract][Full Text] [Related]
15. Efficacy, safety and pharmacokinetic study of a novel fentanyl-containing matrix transdermal patch system in Japanese patients with cancer pain.
Miyazaki T; Hanaoka K; Namiki A; Ogawa S; Kitajima T; Hosokawa T; Ishida T; Nogami S; Mashimo S
Clin Drug Investig; 2008; 28(5):313-25. PubMed ID: 18407717
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients with cancer and chronic non-cancer pain.
Clark AJ; Ahmedzai SH; Allan LG; Camacho F; Horbay GL; Richarz U; Simpson K
Curr Med Res Opin; 2004 Sep; 20(9):1419-28. PubMed ID: 15383190
[TBL] [Abstract][Full Text] [Related]
17. Transdermal fentanyl for cancer pain.
Hadley G; Derry S; Moore RA; Wiffen PJ
Cochrane Database Syst Rev; 2013 Oct; 2013(10):CD010270. PubMed ID: 24096644
[TBL] [Abstract][Full Text] [Related]
18. Systematic review of adverse events of buprenorphine patch versus fentanyl patch in patients with chronic moderate-to-severe pain.
Wolff RF; Reid K; di Nisio M; Aune D; Truyers C; Hernandez AV; Misso K; Riemsma R; Kleijnen J
Pain Manag; 2012 Jul; 2(4):351-62. PubMed ID: 24654721
[TBL] [Abstract][Full Text] [Related]
19. [Transdermal System-Buprenorphine and Fentanyl].
Sakurai H
Masui; 2015 Nov; 64(11):1145-50. PubMed ID: 26689065
[TBL] [Abstract][Full Text] [Related]
20. Transdermal fentanyl. A review of its pharmacological properties and therapeutic efficacy in pain control.
Jeal W; Benfield P
Drugs; 1997 Jan; 53(1):109-38. PubMed ID: 9010652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
